系统性红斑狼疮：回顾2025年。

IF 3.4 4区医学 Q2 RHEUMATOLOGY

Clinical and experimental rheumatology Pub Date : 2025-03-01 Epub Date: 2025-03-12 DOI:10.55563/clinexprheumatol/m0pi1k

Angela Elia, Dina Zucchi, Ettore Silvagni, Marco Oliva, Giancarlo Cascarano, Chiara Cardelli, Benedetta Ciribè, Alessandra Bortoluzzi, Chiara Tani

{"title":"系统性红斑狼疮：回顾2025年。","authors":"Angela Elia, Dina Zucchi, Ettore Silvagni, Marco Oliva, Giancarlo Cascarano, Chiara Cardelli, Benedetta Ciribè, Alessandra Bortoluzzi, Chiara Tani","doi":"10.55563/clinexprheumatol/m0pi1k","DOIUrl":null,"url":null,"abstract":"This review highlights key advancements in systemic lupus erythematosus (SLE) research during 2024, covering pathogenesis, novel therapies, biomarkers, and clinical outcomes. Notable findings include new insights into immune dysregulation, promising therapeutic targets, and real-world data confirming the efficacy of anifrolumab and belimumab. Advances in biomarkers enhance disease monitoring, while multidisciplinary approaches improve reproductive outcomes and quality of life. These developments contribute to refining SLE treatment strategies and patient management.","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":"43 3","pages":"397-406"},"PeriodicalIF":3.4000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Systemic lupus erythematosus: one year in review 2025.\",\"authors\":\"Angela Elia, Dina Zucchi, Ettore Silvagni, Marco Oliva, Giancarlo Cascarano, Chiara Cardelli, Benedetta Ciribè, Alessandra Bortoluzzi, Chiara Tani\",\"doi\":\"10.55563/clinexprheumatol/m0pi1k\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"This review highlights key advancements in systemic lupus erythematosus (SLE) research during 2024, covering pathogenesis, novel therapies, biomarkers, and clinical outcomes. Notable findings include new insights into immune dysregulation, promising therapeutic targets, and real-world data confirming the efficacy of anifrolumab and belimumab. Advances in biomarkers enhance disease monitoring, while multidisciplinary approaches improve reproductive outcomes and quality of life. These developments contribute to refining SLE treatment strategies and patient management.\",\"PeriodicalId\":10274,\"journal\":{\"name\":\"Clinical and experimental rheumatology\",\"volume\":\"43 3\",\"pages\":\"397-406\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2025-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical and experimental rheumatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.55563/clinexprheumatol/m0pi1k\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/3/12 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and experimental rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.55563/clinexprheumatol/m0pi1k","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/12 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

本文综述了2024年系统性红斑狼疮（SLE）研究的主要进展，包括发病机制、新疗法、生物标志物和临床结果。值得注意的发现包括对免疫失调的新见解，有希望的治疗靶点，以及证实anifrolumab和belimumab疗效的实际数据。生物标志物的进步加强了疾病监测，而多学科方法改善了生殖结果和生活质量。这些进展有助于完善SLE治疗策略和患者管理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Systemic lupus erythematosus: one year in review 2025.

This review highlights key advancements in systemic lupus erythematosus (SLE) research during 2024, covering pathogenesis, novel therapies, biomarkers, and clinical outcomes. Notable findings include new insights into immune dysregulation, promising therapeutic targets, and real-world data confirming the efficacy of anifrolumab and belimumab. Advances in biomarkers enhance disease monitoring, while multidisciplinary approaches improve reproductive outcomes and quality of life. These developments contribute to refining SLE treatment strategies and patient management.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical and experimental rheumatology 医学-风湿病学

CiteScore

6.10

自引率

18.90%

发文量

377

审稿时长

3-6 weeks

期刊介绍： Clinical and Experimental Rheumatology is a bi-monthly international peer-reviewed journal which has been covering all clinical, experimental and translational aspects of musculoskeletal, arthritic and connective tissue diseases since 1983.